Partners in the seed financing included Thiel Capital, Bioverge, Sanford Biosciences and Christian Angermayer's Presight Capital.
Kevin Kalish has over 15 years' experience leading R and D, Program Management and Operations with Medtronic, Boston Scientific and Johnson and Johnson. Most recently he provided strategic leadership to the Transformative Solutions business unit at Medtronic.
He received his MBA from Boston College, BSE/MSE from UMass Lowell and is Program Management Professional certified.
EnClear Therapies is a Cambridge based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of neurodegenerative diseases and provide closed loop delivery and monitoring of cerebrospinal fluids.
The company's first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer